Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.

Published

Journal Article

UNLABELLED: To determine persistence with subcutaneous denosumab every 6 months in women being treated for osteoporosis, we conducted a single-arm prospective, observational study in the United States and Canada. Among 935 patients enrolled, 12-month persistence was 82%, with 66 patients (7%) reporting serious adverse events and 19 patients (2%) reporting fractures. INTRODUCTION: Increased persistence with osteoporosis therapy is associated with reduced fracture risk. Denosumab reduced fracture risk in clinical trials; persistence in community settings is undetermined. This study evaluates persistence with denosumab in community practice in the United States (US) and Canada. METHODS: In a 24-month multicenter, prospective, single-arm, observational study, women being treated for osteoporosis were enrolled ≤4 weeks after the first subcutaneous injection of denosumab. For this 12-month prespecified interim analysis, endpoints include persistence (one injection at study entry and another within 6 months + 8 weeks), attributes associated with persistence (univariate analysis), and serious adverse events (SAEs). RESULTS: Among 935 patients (mean age 71 years), mean baseline T-scores were -2.18 (femoral neck) and -2.00 (lumbar spine); 50% of patients had experienced osteoporotic fracture(s). At 12 months, 82 % of patients were persistent with denosumab. Baseline factors significantly (p < 0.05) associated with higher persistence included use of osteoporosis medications >5 years previously, lumbar spine T-score > -2.5, and treatment by female physicians (US). Lower persistence was associated (p < 0.05) with psychiatric diagnoses including depression, southern US residence, being divorced, separated, or widowed (US), and prior hip fracture (Canada). SAEs were reported in 66 patients (7%); no SAEs of osteonecrosis of the jaw, atypical femoral fracture, fracture healing complications, hypocalcemia, eczema, or hypersensitivity were reported. Nineteen patients (2%) reported osteoporotic fractures. CONCLUSIONS: The 12-month persistence observed in this single-arm open-label study of US and Canadian community practice extends the evidence regarding denosumab's potential role in reducing fracture risk in postmenopausal women with osteoporosis.

Full Text

Duke Authors

Cited Authors

  • Silverman, SL; Siris, E; Kendler, DL; Belazi, D; Brown, JP; Gold, DT; Lewiecki, EM; Papaioannou, A; Simonelli, C; Ferreira, I; Balasubramanian, A; Dakin, P; Ho, P; Siddhanti, S; Stolshek, B; Recknor, C

Published Date

  • January 2015

Published In

Volume / Issue

  • 26 / 1

Start / End Page

  • 361 - 372

PubMed ID

  • 25236877

Pubmed Central ID

  • 25236877

Electronic International Standard Serial Number (EISSN)

  • 1433-2965

Digital Object Identifier (DOI)

  • 10.1007/s00198-014-2871-6

Language

  • eng

Conference Location

  • England